Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Revenue (2022 - 2026)

Indivior Pharmaceuticals has reported Revenue over the past 5 years, most recently at $317.0 million for Q1 2026.

  • For Q1 2026, Revenue rose 19.17% year-over-year to $317.0 million; the TTM value through Mar 2026 reached $1.3 billion, up 10.34%, while the annual FY2025 figure was $1.2 billion, 4.29% up from the prior year.
  • Revenue for Q1 2026 was $317.0 million at Indivior Pharmaceuticals, down from $358.0 million in the prior quarter.
  • Over five years, Revenue peaked at $358.0 million in Q4 2025 and troughed at $221.0 million in Q2 2022.
  • A 5-year average of $283.2 million and a median of $288.5 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: rose 24.89% in 2023 and later dropped 6.34% in 2025.
  • Year by year, Revenue stood at $241.0 million in 2022, then rose by 21.58% to $293.0 million in 2023, then grew by 1.71% to $298.0 million in 2024, then rose by 20.13% to $358.0 million in 2025, then fell by 11.45% to $317.0 million in 2026.
  • Business Quant data shows Revenue for INDV at $317.0 million in Q1 2026, $358.0 million in Q4 2025, and $314.0 million in Q3 2025.